Cognitive Deficits in Schizophrenia and Alcoholism: A Review of the Evidence and Findings on the Effects of Treatment on Cognitive Functioning in Patients With Dual Diagnoses

被引:4
作者
Ralevski, Elizabeth [1 ]
Gianoli, Mayumi O. [1 ]
Russo, Melanie [1 ]
Dwan, Rita [1 ]
Radhakrishnan, Rajiv [1 ]
机构
[1] Yale Univ, Sch Med, Dept Psychiat, West Haven, CT 06516 USA
关键词
dual diagnosis; schizophrenia; alcohol dependence; alcohol use disorders; cognitive functioning; treatment; GLYCINE TRANSPORT INHIBITORS; HALSTEAD CATEGORY TEST; SUBSTANCE-ABUSE; CHOLINESTERASE-INHIBITORS; NEUROCOGNITIVE FUNCTION; SOCIAL COGNITION; MEMORY FUNCTION; IMPAIRMENT; METAANALYSIS; DYSFUNCTION;
D O I
10.1080/15504263.2012.696534
中图分类号
B849 [应用心理学];
学科分类号
040203 ;
摘要
Objective: Although cognitive deficits have been carefully studied in both schizophrenia disorders and alcohol use disorders, comparatively little is known about cognitive deficits in patients with dual diagnoses of schizophrenia and alcohol use disorders. The main objectives of this article are (a) to review the literature on cognitive functioning in patients with dual diagnoses of schizophrenia and alcohol use disorders, and (b) to summarize the studies that have examined the effects of treatments on cognitive functioning in patients with these dual diagnoses. Methods: We identified and reviewed 10 studies that examined cognitive functioning in patients with schizophrenia and alcohol use disorders. We also identified and reviewed three studies that reported on treatments for cognitive deficits in patients with dual diagnoses of schizophrenia and alcohol use disorders. Results: Overall, patients with dual diagnoses of schizophrenia and alcohol use disorders were more cognitively impaired than those with a single diagnosis of schizophrenia or alcohol use disorders. The literature on the effects of treatment on cognitive functioning in patients with dual diagnoses is very limited, and the results indicate no effects of pharmacological treatments on cognitive functioning despite improvement in psychotic symptoms and/or abstinence from alcohol. Conclusions: There is a need for more systemic and rigorous study of cognitive deficits and their treatments in patients with dual diagnoses of schizophrenia and alcohol use disorders. (Journal of Dual Diagnosis, 8: 205-217, 2012)
引用
收藏
页码:205 / 217
页数:13
相关论文
共 50 条
  • [21] Aspects of cognitive functioning in schizotypy and schizophrenia: Evidence for a continuum model
    Cochrane, Mary
    Petch, Ian
    Pickering, Alan D.
    PSYCHIATRY RESEARCH, 2012, 196 (2-3) : 230 - 234
  • [22] Adrenergic targets for the treatment of cognitive deficits in schizophrenia
    Arnsten, AFT
    PSYCHOPHARMACOLOGY, 2004, 174 (01) : 25 - 31
  • [23] Adrenergic targets for the treatment of cognitive deficits in schizophrenia
    Amy F. T. Arnsten
    Psychopharmacology, 2004, 174 : 25 - 31
  • [24] Treatment of cognitive deficits in schizophrenia - Part 2: Pharmacological strategies
    Roesch-Ely, D.
    Pfueller, U.
    Mundt, C.
    Mueller, U.
    Weisbrod, M.
    NERVENARZT, 2010, 81 (05): : 564 - 576
  • [25] The effects of donepezil on phencyclidine-induced cognitive deficits in a mouse model of schizophrenia
    Li, Yi-Xuan
    Ye, Zi-He
    Chen, Tong
    Jia, Xiao-Feng
    He, Ling
    PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, 2018, 175 : 69 - 76
  • [26] Rivastigmine treatment as an add-on to antipsychotics in patients with schizophrenia and cognitive deficits
    Chouinard, Sylvie
    Stip, Emmanuel
    Poulin, Julie
    Melun, Jean-Pierre
    Godbout, Roger
    Guillem, Francois
    Cohen, Henri
    CURRENT MEDICAL RESEARCH AND OPINION, 2007, 23 (03) : 575 - 583
  • [27] Cognitive deficits and cognitive training in schizophrenic patients: a review
    Rund, BR
    Borg, NE
    ACTA PSYCHIATRICA SCANDINAVICA, 1999, 100 (02) : 85 - 95
  • [28] The use of the Montreal Cognitive Assessment (MoCA) screening tool to evaluate cognitive deficits in Lebanese in-patients with schizophrenia
    Haddad, Chadia
    Salameh, Pascale
    Sacre, Hala
    Clement, Jean-Pierre
    Calvet, Benjamin
    ASIAN JOURNAL OF PSYCHIATRY, 2022, 70
  • [29] Evidence of Systematic Attenuation in the Measurement of Cognitive Deficits in Schizophrenia
    Thomas, Michael L.
    Patt, Virginie M.
    Bismark, Andrew
    Sprock, Joyce
    Tarasenko, Melissa
    Light, Gregory A.
    Brown, Gregory G.
    JOURNAL OF ABNORMAL PSYCHOLOGY, 2017, 126 (03) : 312 - 324
  • [30] The role of cannabis in cognitive functioning of patients with schizophrenia
    Schnell, Thomas
    Koethe, Dagmar
    Daumann, Joerg
    Gouzoulis-Mayfrank, Euphrosyne
    PSYCHOPHARMACOLOGY, 2009, 205 (01) : 45 - 52